The company is still reeling from the impact of expenses related to litigation, additional DePuy ASR Hip recall costs and the recent acquisition of Synthes. The company spent $233 million on litigation and recall expenses.
Read the financial report for DePuy Orthopaedics.
Related Articles to DePuy:
DePuy Orthopaedics’ Foot and Hip System Receive FDA 510(k) Clearance
DePuy Orthopaedics Names Andrew Ekdahl President
DePuy’s New Ceramic-on-Metal Hip Implant Receives FDA Clearance
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
